MICHELLE REED: Open Payments
NPI 1043753973 · READING, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,019 in 120 payments from 11 companies in 2025. Trend: 2023 $565 · 2024 $2,736 · 2025 $4,019
Food & beverage: $4,000Education: $19
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $656 |
| Alkermes, Inc. | 13 | $610 |
| Axsome Therapeutics, Inc. | 8 | $478 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $469 |
| E.R. Squibb & Sons, L.L.C. | 9 | $381 |
| Teva Pharmaceuticals USA, Inc. | 22 | $369 |
| Neurocrine BioSciences, Inc. | 5 | $304 |
| Otsuka America Pharmaceutical, Inc. | 9 | $263 |
| Janssen Pharmaceuticals, Inc | 12 | $222 |
| Vanda Pharmaceuticals Inc. | 8 | $157 |
Products named: VRAYLAR, Auvelity, CAPLYTA, COBENFY, REXULTI, INGREZZA, ARISTADA, LYBALVI.
Industry payments across PA — which companies pay providers there.
